Skip to content
PeptideAgent

Peptides for HIV associated lipodystrophy: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Tesamorelin (Egrifta) is FDA approved to reduce excess abdominal fat in adults with HIV associated lipodystrophy. In phase 3 trials it cut visceral fat by about 15% versus placebo over 26 weeks and lowered triglycerides, and a separate trial found a 37% relative reduction in liver fat. The benefit depends on continued treatment.

Evidence: Strongest: Human RCT evidence1 peptide gradedVerified: Verified Sep 23, 2026

Do peptides help with HIV associated lipodystrophy?

One peptide is graded for HIV associated lipodystrophy on this page. The strongest grade is human RCT evidence, for tesamorelin. It is weighed against the standard of care below, and the evidence table gives its grade and a note.

What is the standard of care for HIV associated lipodystrophy?

Switch away from older antiretrovirals linked to fat changes where possible; diet and exercise; manage lipids and glucose; tesamorelin for excess visceral abdominal fat; injectable fillers for facial fat loss.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for HIV associated lipodystrophy?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for HIV associated lipodystrophy with evidence grades
PeptideEvidence for this useNote
TesamorelinEvidence: Human RCT evidencePooled phase 3 data (n = 806): visceral fat minus 15.4% versus placebo and triglycerides down 37 mg/dL, with no meaningful glucose change; effect maintained at 52 weeks only with continued treatment. [2] [3] [5]

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for HIV associated lipodystrophy?

Tesamorelin has the strongest evidence among the peptides graded here, at human RCT evidence. Pooled phase 3 data (n = 806): visceral fat minus 15.4% versus placebo and triglycerides down 37 mg/dL, with no meaningful glucose change; effect maintained at 52 weeks only with continued treatment. [2] [3] [5]

Is any peptide FDA approved for HIV associated lipodystrophy?

Tesamorelin is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to HIV associated lipodystrophy. [2] [3] [5] [6]

Has any peptide been tested in a randomized trial for HIV associated lipodystrophy?

Yes, for tesamorelin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3] [5]

From the blog

More on the blog

Sources

  1. [1]Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007PubMed 18057338, 2007
  2. [2]Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataPubMed 20554713, 2010
  3. [3]Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelinPubMed 22495074, 2012
  4. [4]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialPubMed 31611038, 2019
  5. [5]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
  6. [6]Drugs@FDA: FDA-approved drugs databaseFDA